text:
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body, where they can damage tissue or form lesions. For most patients with LCH, standard-of-care vinblastine/prednisone are used as front-line therapy while cytarabine therapy has been used as therapy for patients who develop recurrence. No alternate treatment strategy has been developed for frontline therapy in LCH. The purpose of this research study is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH. We will evaluate the utility of an imaging study called a positron emission tomography (PET) scan to more accurately assess areas of LCH involvement not otherwise seen in other imaging studies as well as response to therapy. We also want to identify if genetic and other biomarkers (special proteins in patient's blood and in patient's cancer) relate to the response of patients LCH to study treatment.
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages
|N/A - 21 Years
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
|Phase 3
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
|Baylor College of Medicine
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Olive Eckstein, MD
|Principal Investigator Affiliation
|Baylor College of Medicine
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
|Overall Status
|United States
The disease, disorder, syndrome, illness, or injury that is being studied.
|Langerhans Cell Histiocytosis
To be eligible to participate in this study, patients physician must have determined that they have LCH which is not treatable by surgical intervention or observation alone. If patient chooses to participate in this study, they will be assigned randomly (like flipping a coin) to one of two LCH chemotherapy treatment groups. A computer will randomly determine if they will begin to receive vinblastine/prednisone treatment or cytarabine treatment. Patient will have an equal chance (50%) to receive vinblastine/prednisone or to receive cytarabine. Neither the patient nor their doctor will be able to choose the group assignment, but the patient and their study doctor will know which treatment they are receiving. The patient will need to have the following tests, exams, or procedures. Most of these are part of regular cancer care and may be done even if the patient does not want to join this study. Some of them may not need to be repeated if they have had them done recently. The patient's doctor will tell them which ones they need to repeat.
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Texas Children's Hospital
Houston, Texas, 77030
Site Contact
Olive Eckstein, MD


text:
Study on toxic heavy metals in Indian Carp (C.catla) and vegetation of Bhavan's College Lake of Andheri, Mumbai Online publication date: Fri, 17-May-2013
by Pravin U. Singare; Madhumita S. Talpade
Interdisciplinary Environmental Review (IER), Vol. 14, No. 1, 2013
Abstract: The present paper deals with ecological study with reference to the accumulation of toxic heavy metals in the fishes and vegetation collected along the Bhavan's College Lake of Andheri, Mumbai. It was observed that the yearly average concentration of Pb, Zn, Cd, As, Cu and Fe in vegetation samples were 0.08, 0.15, 0.006, 0.45, 7.73 and 52.4 ppm respectively, which was higher than 0.05, 0.05, 0.005, 0.3, 0.04, and 42.5 ppm respectively as found in fish samples. However, yearly average concentration of Hg, Cr, Ni and Ca in fish samples were found to be 0.04, 0.25, 0.19 and 86 ppm respectively which was higher than 0.03, 0.21, 0.09 and 71.3 ppm respectively as found in vegetation samples. It is expected that the present study will be useful to understand the bio-accumulation and biomagnifications of toxic heavy metals in aquatic life.
Online publication date: Fri, 17-May-2013
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the Interdisciplinary Environmental Review (IER):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email email@example.com

subset: commoncrawl